Lilly appoints new chief ethics and compliance officer and senior VP
pharmafile | October 30, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Melissa Barnes, lilly
Eli Lilly has announced that Melissa Barnes will be promoted to chief ethics and compliance officer and senior vice president of enterprise risk management.
Barnes will replace Anne Nobles, who will retire at the end of the year. Barnes, vice president and deputy general counsel, is currently responsible for litigation, compliance and speciality legal areas, including regulatory and human resources.
In her new role, Barnes will report to John Lechleiter, chairman, president and chief executive, and will serve on the company’s executive committee.
Lechleiter said: “Melissa’s legal background and extensive experience at Lilly make her the right person to assume this important role within our company.”
Barnes is a graduate of Harvard Law School. She joined the company in 1994 and has served in a number of legal and business positions at Lilly, specialising in legal work related to compliance, litigation, human resources, regulatory, business management strategy, and global marketing and sales.
Nobles joined Lilly in 1990 and has served in various leadership positions, including vice president of corporate affairs. She became Lilly’s chief compliance officer in 2007 and has served on the company’s executive committee since 2009.
“Anne has provided critical leadership at a very important time for our company,” said Lechleiter. “Her contributions have been instrumental in building a comprehensive company-wide ethics and compliance programme. She has worked closely with Lilly business leaders to ensure that compliance is effectively integrated into our business plans and our day-to-day activities.”
Related Content
NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE
BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute …
Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy
The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the …
Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial
Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and …
